Kazia recently completed recruitment for the phase II clinical trial testing its development drug paxalisib on aggressive brain cancer.
() (NASDAQ:KZIA) substantial shareholder The Bank of New York Mellon Corporation has increased its shareholding to 28.54%.
A number of purchases throughout the month of March 2020 has grown the holding from 19.79 million shares to 20.59 million shares.
Trial recruitment recently completed
Kazia is an oncology-focused biotechnology company developing the drug paxalisib to treat brain cancer.
The company recently completed recruitment for the phase II clinical trial in newly-diagnosed glioblastoma (aggressive brain cancer).
30 patients were recruited at six sites in the US and the final patient commenced dosing on 27 February 2020.
Kazia has been accepted for a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting in San Diego, CA on 24-29 April 2020.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE